Artiva Biotherapeutics, Inc.
ARTV
$11.78
$0.564.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -21.40% | -28.29% | -29.23% | -131.00% | -176.21% |
| Total Depreciation and Amortization | 6.59% | 6.83% | 5.56% | 7.26% | 8.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.38% | -40.00% | -46.29% | -27.36% | 21.84% |
| Change in Net Operating Assets | 30.32% | -30.46% | -337.51% | 92.12% | 103.84% |
| Cash from Operations | -30.23% | -39.47% | -50.18% | -37.64% | -23.85% |
| Capital Expenditure | -104.23% | -302.96% | -83.69% | -33.08% | 19.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 159.66% | 155.08% | 140.21% | -1,165.88% | -822.34% |
| Cash from Investing | 157.17% | 152.64% | 137.99% | -1,360.99% | -739.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 27.47% | 11.41% | -12.93% | -75.64% | -- |
| Issuance of Common Stock | -100.00% | -99.92% | -99.90% | 757,509.09% | 1,666,860.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 105.68% | 105.57% | 106.65% | -110.90% | -116.60% |
| Cash from Financing | -100.21% | -99.99% | -99.94% | 620.06% | 565.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.32% | -0.47% | -201.58% | 71.32% | 53.94% |